Abstract
There is an unquestionable need for more effective therapies for pancreatic cancer. Aptamers are single-stranded DNA or RNA oligonucleotide ligands whose 3-dimensional structures are dictated by their sequences. Aptamers have been generated against numerous purified protein targets using an iterative in vitro selection technique known as Systematic Evolution of Ligands by EXponential enrichment (SELEX). Several biochemical properties make them attractive tools for use in an array of biological research applications and as potential pharmacologic agents. Isolated aptamers may directly affect target protein function, or they may also be modified for use as delivery agents for other therapeutic cargo or as imaging agents. More complex selections, using whole cancer cells or tumor tissue, may simultaneously identify novel or unexpected targets and aptamers to inhibit them. This review summarizes recent advances in the field of aptamers and discusses aptamer targets that have relevance to pancreatic cancer.
Keywords: Aptamer, cancer therapy, pancreatic cancer, RNA therapeutic, SELEX
Anti-Cancer Agents in Medicinal Chemistry
Title: Aptamers: Potential Applications to Pancreatic Cancer Therapy
Volume: 11 Issue: 5
Author(s): Kristy L. Rialon and Rebekah R. White
Affiliation:
Keywords: Aptamer, cancer therapy, pancreatic cancer, RNA therapeutic, SELEX
Abstract: There is an unquestionable need for more effective therapies for pancreatic cancer. Aptamers are single-stranded DNA or RNA oligonucleotide ligands whose 3-dimensional structures are dictated by their sequences. Aptamers have been generated against numerous purified protein targets using an iterative in vitro selection technique known as Systematic Evolution of Ligands by EXponential enrichment (SELEX). Several biochemical properties make them attractive tools for use in an array of biological research applications and as potential pharmacologic agents. Isolated aptamers may directly affect target protein function, or they may also be modified for use as delivery agents for other therapeutic cargo or as imaging agents. More complex selections, using whole cancer cells or tumor tissue, may simultaneously identify novel or unexpected targets and aptamers to inhibit them. This review summarizes recent advances in the field of aptamers and discusses aptamer targets that have relevance to pancreatic cancer.
Export Options
About this article
Cite this article as:
L. Rialon Kristy and R. White Rebekah, Aptamers: Potential Applications to Pancreatic Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/187152011795677472
DOI https://dx.doi.org/10.2174/187152011795677472 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets 5-HT5 Receptors
Current Drug Targets - CNS & Neurological Disorders Targeting G-Quadruplex DNA for Cancer Chemotherapy
Current Drug Discovery Technologies Molecular Probes for Malignant Melanoma Imaging
Current Pharmaceutical Biotechnology Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy The Arrestin Fold: Variations on a Theme
Current Genomics Editorial (Thematic Issue: GPCR-Targeted Drug Development)
Current Drug Targets The Role of NF-κB Inhibitors in Cell Response to Radiation
Current Medicinal Chemistry Modified cAMP Derivatives: Powerful Tools in Heart Research
Current Medicinal Chemistry Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Clinical Cancer Drugs Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells
Anti-Cancer Agents in Medicinal Chemistry Integrin-Mediated Drug Resistance
Current Signal Transduction Therapy Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry The Application of Peptides in Glioma: A Novel Tool for Therapy
Current Pharmaceutical Biotechnology Assessing the Neuronal Serotonergic Target-based Antidepressant Stratagem: Impact of In Vivo Interaction Studies and Knockout Models
Current Neuropharmacology Brain-Derived Neurotrophic Factor (BDNF) has Proliferative Effects on Neural Stem Cells through the Truncated TRK-B Receptor, MAP Kinase, AKT, and STAT-3 Signaling Pathways
Current Neurovascular Research